Caprion’s leading and proprietary proteomics discovery technologies - CellCarta® - enable the discovery of novel targets for therapeutics development and the identification of novel protein biomarkers that can significantly reduce risk and enhance clinical development productivity and decision making in Pharmaceutical research.

Caprion Proteomics wins Frost & Sullivan Award

Details...

 

U.S. National Institutes of Health (NIH)

choose Caprion's distinctive, quantitative protein profiling technologies to analyze pathogen and host proteins involved during Brucella (a potential bioterrorism agent) infection. 

Details...

 

 

Ranks Caprion amongst "fast 15" within life sciences companies.

Details...

 

 

News

March 25, 2009

Caprion article in Genetic Engineering & biotechnology News: "Personalized Medicine Grows in Fits and Starts" March 1st 2009 issue (Volume 29, Number 5)

December 16, 2008

CAPRION PROTEOMICS INC. ANNOUNCES STRATEGIC MARKETING AND DISTRIBUTION ALLIANCE WITH COVANCE INC.

December 16, 2008

COVANCE PURCHASES EQUITY STAKE IN CAPRION PROTEOMICS

›› archive

Events

July 19 - 23, 2009

AACC American Association for Clinical Chemistry: John Kamins attending

Chicago, Il., USA

September 26 - 30, 2009

Hupo 2009

Toronto Ont., Canada

October 7 - 8, 2009

BioContact Québec; Martin Leblanc presenting

Québec City, Canada

October 11 - 13, 2009

Bio Japan World Business Forum - Canadian Embassy in Tokyo; Didier JeanFrançois attending

Yokohama, Japan

›› archive